Reported results
- U.S. sales were $347,039 for the quarter ended September 30, 2026, compared to $336,594 for the same period in 2025.
- Overall sales were $404,597 for the quarter ended September 30, 2026, compared to $729,394 for the same period in 2025.
- Research and development expenses were $1,942,927 for the quarter ended September 30, 2026, compared to $1,382,022 for the same period in 2025.
- Net loss was $4,564,815, or ($0.53) per basic and diluted share, for the quarter ended September 30, 2026.
- Cash and cash equivalents were approximately $23.9 million as of September 30, 2026.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
